Seattle Genetics, Inc. and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer
Published: Sep 13, 2011
BOTHELL, Wash. & OXFORD, England--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Oxford BioTherapeutics (OBT) today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP®) database. The antibodies generated by OBT will then be screened for activity using Seattle Genetics’ ADC technology. The resulting ADCs may be selected by each company for further development and commercialization.